Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 21, 2025 -- Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, according to a research letter published online Jan. 17 in JAMA Health Forum.
Ashwin K. Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide, tirzepatide, and liraglutide.
The researchers found that 98 unique websites sold any GLP-1 RA during the study period; the analysis included 79 of these websites that sold compounded GLP-1 RAs or a prescription for compounded medications. All 79 websites sold compounded semaglutide and 72.2 and 3.8 percent sold compounded tirzepatide and liraglutide, respectively. Overall, 52 websites featured a mark of certification; 50 displayed LegitScript certification. Two websites required a prior prescription for compounded GLP-1 RAs and did not provide a prescription. Eleven and seven of the websites did not disclose GLP-1 RAs were compounded and referred to compounded medications as generic, respectively. Thirty-four of the websites stated that the compounded medications were not FDA approved, while 29 stated or implied that these drugs were approved. Adverse effects, warnings and precautions, and contraindications of compounded GLP-1 RAs were not reported by 39 websites (49.4 percent), while 32 sites advertised an efficacy claim not in the authorized label of the FDA-approved branded GLP-1 RA.
"Enhanced regulatory guidance and oversight are needed to clarify criteria for 'truthful, non-misleading, and accurate' advertising to ensure consumers are informed of the risks and benefits of compounded GLP-1 RAs and other compounded medications," the authors write.
Several authors disclosed ties to industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Many Medicaid Enrollees Have Restricted Access to SGLT2 Inhibitors, GLP-1 Receptor Agonists
WEDNESDAY, April 30, 2025 -- Many Medicaid enrollees with type 2 diabetes have restricted access to cardioprotective medications, including sodium-glucose cotransporter-2...
Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes
WEDNESDAY, April 30, 2025 -- Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study...
Adverse Pregnancy Outcomes Partly Mediate Association Between Prepregnancy Obesity, CVD Risk
MONDAY, April 21, 2025 -- Adverse pregnancy outcomes (APOs) mediate a small proportion of the association between prepregnancy obesity and cardiovascular disease (CVD) risk in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.